Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from argenx

Chart of the Day: Argenx - Great Biotech

The Chart of the Day belongs to the biotechnology company Argenx (ARGX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature...

Barchart

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Upgrades

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Benzinga

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases. According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

Benzinga

Golden Cross Appears Before argenx Investors

If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

Recap: argenx Q1 Earnings

argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022

Upgrades

Benzinga

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19 vaccine candidate. Results from the efficacy analysis have been submitted to the Vietnam Ministry of Health by Vinbiocare on April 13 and shared with Arcturus in parallel with this filing. The Phase…

Benzinga

Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores

Argenx SE (NASDAQ: ARGX) announced

Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.

Benzinga

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx SE (NASDAQ: ARGX) ) has

Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What 8 Analyst Ratings Have To Say About argenx

argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:

Benzinga

Recap: argenx Q4 Earnings

argenx (NASDAQ:ARGX) reported its Q4 earnings results on Thursday, March 3, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

Benzinga

argenx's Earnings: A Preview

argenx (NASDAQ:ARGX) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that argenx will report an earnings per share (EPS) of $-4.82.

Benzinga

What 8 Analyst Ratings Have To Say About argenx

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

1 2

People

Christopher Raymond

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.